The Brazilian Society of Rheumatology guidelines for axial spondyloarthritis – 2019

Table 4 Relative risks of different safety outcomes and respective 95% CIs calculated using a normal approximation. Data from different studies were pooled when the same outcomes from the same treatments were available and when they referred to doses and/or regimens approved in Brazil

Outcome	Serious adverse effects		Discontinuation for any cause
	Follow-up time (weeks)
	12 to 24
Drug	Relative risk	95% CI	Relative risk	95% CI
Infliximab [111]	1.30	0.28–6.12	0.78	0.14–4.15
Etanercept [113, 119, 120, 123]	0.84	0.37–1.91	0.81	0.47–1.42
Adalimumab [126, 130, 131]	1.59	0.49–5.06	1.49	0.65–3.39
Golimumab [133, 137, 138]	0.94	0.35–2.56	1.19	0.52–2.75
Certolizumab pegol [139]	1.18	0.43–3.36	0.74	0.34–1.58
Secukinumab [142]	0.81	0.34–1.92	0.55	0.26–1.16

ISSN: 2523-3106